Compare Innovative Industrial Properties Inc (IIPR) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Innovative Industrial Properties Inc vs Sana Biotechnology Inc — how do they compare? Innovative Industrial Properties Inc trades at $62.07 (market cap $1.87B), while Sana Biotechnology Inc trades at $3.23 (market cap $873.84M). The key difference: Innovative Industrial Properties Inc is far larger — about 2.1× Sana Biotechnology Inc's market cap, and Innovative Industrial Properties Inc pays a 11.81% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| IIPR | SANA | |
|---|---|---|
Market Cap | $1.87B | $873.84M |
Sector | Real Estate | Health |
52-Week High | $64.67 | $5.92 |
52-Week Low | $44.58 | $2.68 |
Enterprise Value | $2.25B | $848.03M |
Dividend Yield | 11.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IIPR trades at $64.35, down slightly today, amid a bullish technical trend with strong moving average support. The REIT reported mixed quarterly earnings, with a significant beat in Q4 2025 but a miss in Q1 2026, while maintaining a high dividend yield. Recent news highlights successful debt management and cannabis rescheduling progress as positive catalysts.
Outlook is cautiously optimistic given the strong balance sheet and regulatory tailwinds, but risks include revenue volatility and high dividend payout. Analyst sentiment is mixed with a slight Hold bias, reflecting concerns over near-term earnings consistency versus long-term growth potential in the cannabis real estate sector.
SANA Biotechnology trades at $3.14, down 0.32% with bearish technical indicators despite strong analyst support. The company shows significant financial challenges with negative ROE of -147.41% and net income of -$244.17M for 2025, though cash burn improved from -$55M to -$12M in 2026. Recent positive developments include a Zacks upgrade to Buy and groundbreaking clinical data published in NEJM.
Investment outlook remains speculative with high execution risk given substantial losses, but strong analyst consensus (82% Buy ratings) reflects optimism about SANA's innovative cell therapy pipeline. Key risks include continued cash burn and clinical trial outcomes, while potential catalysts include successful product development in diabetes and CAR-T therapies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Innovative Industrial Properties Inc
Innovative Industrial Properties Inc is a real estate investment trust engaged in the acquisition, ownership, and management of specialized industrial properties leased to state-licensed operators for their regulated medical-use cannabis facilities. It conducts its business through a traditional umbrella partnership real estate investment trust, or UPREIT structure, in which properties are owned by Operating Partnership, directly or through subsidiaries. Its property portfolio is spread across the United States.
Read more on IIPR →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
